- Achievement increases total production capacity available
to serve international medical markets by 230%
- Brings Aurora's total number of EU GMP certified Canadian
production facilities to 3
- Pharmacies in Germany
have been instructed to resume sales of Aurora's suite of medical
cannabis following temporary pause
NYSE | TSX : ACB
EDMONTON, Feb. 3, 2020 /CNW/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (NYSE | TSX: ACB), the Canadian company
defining the future of cannabis worldwide, announced today its
Aurora River production facility,
located in Bradford, Ontario, has
received European Union Good Manufacturing Practice ("EU GMP")
certification. EU GMP certification is granted to companies whose
production facilities demonstrate a high degree of quality and
consistency in their manufacturing procedures and is a requirement
for the export of medical cannabis products into most European
markets.
In addition, Aurora is pleased to announce it has received all
necessary approvals from local regulators in Germany for sales of its medical cannabis
products, following a temporary sales suspension on certain
products in December 2019. Aurora
will fulfill existing sales orders from inventory currently held in
Germany, ensuring local patients
will have immediate access to medicine from their preferred
pharmacy.
"Aurora is leading the development of medical markets across
Europe and around the world," said
Terry Booth, CEO of Aurora. "The EU
GMP certification of our River facility further validates our
strategy focused on purpose-built facilities, designed and
constructed exclusively for the production of high-quality,
pharmaceutical grade cannabis. I congratulate our team on
successfully working with regulators and licensing bodies to ensure
Aurora's facilities and products are in accordance with local and
international standards that will allow for greater access to the
highest quality medical cannabis products to patients who need
them."
Designed for large scale, high quality production, Aurora River has a cultivation capacity of
28,000 kg per year across its 17 fully-planted, independently
climate-controlled grow rooms. The EU GMP certification of
Aurora River enables the Company to
allocate both a greater quantity of dried and extracted product to
international markets as well as introduce new products grown and
produced in the facility. To date, Aurora has received EU GMP
certification for 3 of its 10 Canadian production facilities.
Aurora River joins Aurora Mountain, located in Mountain View
County, Alberta with a production
capacity of 4,800 kg a year, and Aurora
Ridge located in Markham,
Ontario with a production capacity of 7,000 kg a year, in
achieving this important certification.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with sales and operations in 25 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high-quality consistent product. Designed to be replicable and
scalable globally, our production facilities are designed to
produce cannabis at significant scale, with high quality,
industry-leading yields, and low-per gram production costs. Each of
Aurora's facilities is built to meet European Union Good
Manufacturing Practices ("EU GMP") standards. Certification has
been granted to Aurora's first production facility in Mountain View
County, Aurora Ridge, Aurora River, and its wholly owned European
medical cannabis distributor Aurora Deutschland. All Aurora
facilities are designed and built to the EU GMP standard.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 17 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern
Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia,
HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs,
Whistler, Chemi Pharmaceutical, and Hempco – Aurora is
distinguished by its reputation as a partner and employer of choice
in the global cannabis sector, having invested in and established
strategic partnerships with a range of leading innovators,
including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd.
(ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom
Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH),
Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave
Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group
(private).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and is a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com.
Terry Booth, CEO
Aurora Cannabis Inc.
Forward Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. These forward-looking statements are only
predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions, estimates and
assumptions of management in light of management's experience and
perception of historical trends, current conditions and expected
developments at the date the statements are made, such as current
and future market conditions, the current and future regulatory
environment and future approvals and permits. Forward-looking
statements are subject to a variety of risks, uncertainties and
other factors that management believes to be relevant and
reasonable in the circumstances could cause actual events, results,
level of activity, performance, prospects, opportunities or
achievements to differ materially from those projected in the
forward-looking statements, including general business and economic
conditions, changes in laws and regulations, product demand,
changes in prices of required commodities, competition and other
risks, uncertainties and factors set out under the heading "Risk
Factors" in the Company's annual information form dated
September 10, 2019 (the "AIF") and
filed with Canadian securities regulators available on the
Company's issuer profile on SEDAR at www.sedar.com. The Company
cautions that the list of risks, uncertainties and other factors
described in the AIF is not exhaustive and other factors could also
adversely affect its results. Readers are urged to consider the
risks, uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-receives-eu-gmp-certification-for-its-aurora-river-facility-300997549.html
SOURCE Aurora Cannabis Inc.